<DOC>
	<DOCNO>NCT01696604</DOCNO>
	<brief_summary>This study first administration GSK2849466 human . This single centre , randomize , double-blind , placebo-controlled study , investigate safety , tolerability , pharmacokinetics ( PK ) , pharmacodynamics ( PD ) GSK2849466 , give single repeat oral dose 14 day healthy male subject . Part A randomized placebo control 4-way crossover study . It include two cohort 8 subject . In cohort 4 study period approximately 1 week include 6 day washout . Each subject receive total 3 active dos ascend single oral dose GSK2849466 1 placebo dose course participation study . The first ( `` bridge dose '' ) dose provided subject Cohort 2 last dose provide subject Cohort 1 . The single dos GSK2849466 plan Part A study : 0.01 , 0.03 , 0.1 , 0.3 milligram ( mg ) Cohort 1 0.3 , 1 , 3 , 10 mg Cohort 2 . In cohort 1 2 available safety , tolerability , PK data review prior dose escalation . The dosing schedule Part A may adjust expand cohort add additional cohort ( ) order evaluate additional dos repeat evaluation dose level already study . Part B randomize placebo control , parallel group study . It include three cohort 12 subject . Each subject receive repeat dos GSK2849466 14 day . The dos choose Part B base safety , tolerability , PK data Part A . Subjects Cohort 4 ( and/or another cohort [ ] determine base Part A PK data ) dose fasted state Days 1 14 fed state Day 7 subject receive standard meal 30 minute prior dose . Part B provide sufficient safety tolerability data bridge long duration study . The study duration , include screen follow-up , expect exceed 70 day subject study .</brief_summary>
	<brief_title>A Study Evaluate Safety , Tolerability , Pharmacokinetics , Pharmacodynamics GSK2849466 Healthy Male Subjects</brief_title>
	<detailed_description />
	<mesh_term>Cachexia</mesh_term>
	<criteria>Males 18 50 year age ( inclusive ) , time signing informed consent form . Body weight &gt; =50 kilogram ( kg ) Body Mass Index ( BMI ) within range 19 32 kg/meter ( ) ^2 ( inclusive ) , BMI = ( weight kg ) / ( height meter ) ^2 . Healthy determine responsible experienced physician , base medical evaluation include medical history , physical examination , laboratory test cardiac monitoring . A subject clinical abnormality laboratory parameter outside reference range population study may include Investigator GlaxoSmithKline ( GSK ) Medical Monitor agree find unlikely introduce additional risk factor interfere study procedure . Male subject female partner childbearing potential must agree use one contraception method list Lifestyle Section protocol . This criterion must follow completion followup visit . Capable give write informed consent , include compliance requirement restriction list consent form . Average correct QT interval use Fridericia 's formula ( QTcF ) &lt; 450 millisecond ( msec ) ; QTcF &lt; 480 msec subject Bundle Branch Block . Subjects history clinically significant endocrine , gastrointestinal , hepatic , cardiovascular , neurological , hematological , immunological , renal , respiratory , genitourinary abnormality disease . Subjects history time past coronary artery disease , congestive heart failure , angina , myocardial infarction , cardiac surgery , valvular heart disease , clinically significant arrhythmia , dyspnea , pulmonary edema , stroke , transient ischemic attack . ECG exclusion criterion : Heart rate &lt; 40 &gt; 100 beat per minute ; PR Interval &lt; 120 &gt; 200 msec ; QRS duration &lt; 70 &gt; 110 msec . Subjects history malignancy complete remission least 5 year 1 year nonmelanoma skin carcinoma . Current chronic history liver disease , know hepatic biliary abnormality ( exception Gilbert 's syndrome asymptomatic gallstone ) . History drug alcohol abuse within 5 year prior Screening Period . History regular alcohol consumption within 6 month study define average weekly intake &gt; 14 drink male &gt; 7 drink female . One drink equivalent 12 gram ( g ) alcohol : 12 ounce ( 360 millilitre [ mL ] ) beer , 5 ounce ( 150 mL ) wine 1.5 ounce ( 45 mL ) 80 proof distil spirit . History sensitivity study medication , component thereof history drug allergy , opinion investigator GSK Medical Monitor . Subjects family history early onset prostate cancer multiple member prostate cancer . A positive prestudy drug alcohol screen . Cotinine level indicative smoke history regular use tobaccoor nicotinecontaining product within 6 month prior screen . Subjects value outside specify range follow Key Clinical Laboratory Tests must exclude study : Liver function test Alanine transaminase ( ALT ) , Direct Bilirubin , Albumin &gt; 10 % outside normal reference range ( &lt; 0.9 x low limit normal [ LLN ] &gt; 1.1 x Upper Limit Normal [ ULN ] ) , Renal function Creatinine &lt; 1.6 mg/ deciliter ( dl ) age appropriate Glomerular filtration rate ( GFR ) &gt; =60 mL/min/1.73 m^2 ) , Electrolytes Sodium &gt; + , 5 milliequivalent solute per litre solvent ( mEq/L ) outside normal reference range , Potassium Calcium &gt; 10 % outside normal reference range ( &lt; 0.9 x LLN &gt; 1.1 x ULN ) , Metabolic Glucose &gt; 10 % outside normal reference range ( &lt; 0.9 x LLN &gt; 1.1 x ULN ) Total Cholesterol &gt; 240 mg/dl , Muscle creatine phosphokinase &gt; 2.0 x ULN , Hematology Hemoglobin , WBC , Neutrophils , Platelets &gt; 10 % outside normal reference range ( &lt; 0.9 x LLN &gt; 1.1 x ULN ) , Prostate Specific Antigen ( PSA ) &gt; =2.5 nanogram ( ng ) /mL . A positive test human immunodeficiency virus ( HIV ) antibody . A positive prestudy Hepatitis B surface antigen positive Hepatitis C antibody result within 3 month screen . Exposure four new chemical entity within 12 month prior first dose day . Unable refrain prescription nonprescription drug , include vitamin , herbal dietary supplement ( include St John 's Wort ) within 7 day ( 14 day drug potential enzyme inducer ) 5 halflives ( whichever longer ) prior first dose study medication throughout study , unless opinion Investigator GSK Medical Monitor medication interfere study procedure compromise subject safety . The subject participate clinical trial receive investigational product within following time period prior first dose day current study : 3 month ( 12 week ) , 5 halflives twice duration biological effect investigational product ( whichever longer ) . Where participation study would result donation blood blood product excess 500 mL within 56day period . Unable refrain consumption red wine , seville orange , grapefruit grapefruit juice 7 day prior first dose study medication . Unwillingness inability follow procedure outline protocol</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>safety</keyword>
	<keyword>pharmacokinetics</keyword>
	<keyword>FTIH</keyword>
	<keyword>SARM</keyword>
</DOC>